Calyx EDC Selected for RWE Data Collection in Long Late Phase Trial

NOTTINGHAM, England and MORRISVILLE, North CarolinaFeb. 21, 2022 /PRNewswire/ — Calyx, the provider of eClinical and Regulatory solutions and services that solve complex data challenges in clinical research, today announced that its electronic data capture system data (EDC) has been selected by a leading pharmaceutical company to capture Real World Evidence (RWE) data for a global late phase study.

Calyx EDC selected based on cost effectiveness, speed of delivery and proven long-term data collection capabilities

The global company chose Calyx EDC because of its proven effectiveness in collecting important patient data during long global studies. Calyx’s ability to accelerate delivery of a reliable, cost-effective solution to meet the pharmaceutical company’s accelerated study timelines and ongoing data collection needs was key to its selection.

“We are delighted to work with this leading pharmaceutical company and extend our 30 years of experience in providing reliable, high-quality data to help them fully understand the long-term effects of their medical products,” said Juan Munoz PujolVice-President, IRT and EDC at Calyx.

Click here for more information on Calyx EDC.

About Chalice

Through innovative eClinical and regulatory solutions and services, Calyx turns uncertainty into reliability, helping to bring new medical treatments to market reliably. With deep expertise in clinical development and 30 years of experience serving trial sponsors and clinical research organizations, Calyx uses its intelligence and experience to solve complex problems, deliver rapid insights and bring to market. new drugs every day.

CTMS | EDC | IRT | Medical Imaging | RIM

Go further in your tests with intelligent information on or on LinkedIn, Twitteror facebook.


Quote See original content to download multimedia:

SOURCE Chalice

Comments are closed.